MIRA
INFORM REPORT
|
Report Date : |
22.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
ALBORZ DAROU CO |
|
|
|
|
Registered Office : |
4th
Floor, Alborz Bldg, No.56, Khaled Eslamboli(Vozara) St Beheshti Ave,
Tehran |
|
|
|
|
Country : |
Iran |
|
|
|
|
Date of Incorporation : |
1976 |
|
|
|
|
Com. Reg. No.: |
2455 |
|
|
|
|
Legal Form : |
Public Joint Stock Company |
|
|
|
|
Line of Business : |
Pharmaceutical preparations for the cardiovascular system, central and
autonomic nervous system |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Company
Details
Company
Name: Alborz Darou Co
Headquarter
Address: 4nd Floor, Alborz
Bldg, No.56, Khaled Eslamboli(Vozara) St
Beheshti
Ave
Tehran
Iran
Tel: +98 21 88722434
+98 21 88721517
+98 21 88720127
+98 282 2222990
+98 282 2223004
+98 282 2223005
Fax: +98 21 88721516
+98 282 2223005
Website: www.alborzdarouco.com
E-mail: info@alborzdarouco.com
History
Alborz Darou pharmaceutical company registered as "International
Products Co." in 1976 and was renamed into "Tolipharma Co." in
1979. At last, in 1989 the name of Alborz Darou (Private joint-stock) was
chosen, and then by its introduction to stock exchange in 1996, the company was
changed from "private joint-stock" into general joint-stock".
Registration
& Legal Details
Current Legal Form: Public Joint Stock Company
Registration Address: No.115, 20th
(Abtahi) St, Kordestan Highway
Tehran
Iran
Registration Number: 2455
Registration Date: 1976
Year Established: 1976
Registration Town: Tehran
Capital
Currency: Iranian Rials
Nominal capital: 48,000,000,000
|
Number of Shares: 48,000,000 |
Type of Shares: None Selected |
|
Issued Shares: - |
Value per share: IRI 1,000.00 |
Shareholders
|
Shareholder Names/ Address |
% of Voting/Non-Voting Capital |
|
Alborz Investment Company Tehran Iran |
%18 |
|
KBC Company Tehran Iran |
%12 |
|
Sobhan Pharm
Company Tehran Iran |
%10 |
|
Others Iran |
%45 |
|
Bank Maskan
Investment Tehran Iran |
%15 |
Principals
Name: Mr. Asghar Arefi
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Abdolmajid Cheraghali
Position within the company: Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Morteza Azarnoush
Position within the company: Vice Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Farhad Habibi
Position within the company: Managing Director
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi
Name: Mr. Mohamad Ahmadi
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi
Company
Activities
Pharmaceutical preparations for the
cardiovascular system, central and autonomic nervous system.
Pharmaceutical preparations for metabolism, nutrition,
alimentary systems. Pharmaceutical preparations for urology, dermatology,
gynecology and obstetrics.
Chemotherapeutic agents, endocrines,
antiseptics, immunological preparations.
Local Reporters consider the investigated company to be
Large their field of concern.
Operations
Employees
Company Employs: 300
HQ Premises
Operates from: Owned Offices, Warehouses,
Factory
Location: Central Business Area, Main Road
Branch:
Alborz Darou Factory
Hekmat 8th
St, Alborz Ind City
Qazvin
Iran
Branch is owned
Imports
Imports: Raw Material
Import%: 20%
Import from: Europe, India, Malaysia
Import terms: letters of credit
Additional: balance of 80% purchased via local market
Export
Exports: Finished Goods
Export%: 30%
Export from: Iraq, Afghanistan, CIS
Export terms: letters of credit
Trading
& Selling
Territory: 80% Nationality,
20 % Internationally
Type of Customer: General Public, Local
Authorities
Terms of sales: Cash, letters of credit
Vehicles: Total number of vehicles: 55
Related
Companies
Affiliates:
Alborz Bulk Pharmaceutical Company
No.115, 20th
(abtahi) St, Kordestan Highway
Tehran
Iran
Banks
Export Development
Bank of Iran
Tehran
Iran
Bank Tejarat
Tehran
Iran
Financial
Information
Source: Ms. Kimia Rashad (Secretary)
Currency: Iranian Rials -
000,000
|
Months |
Date |
Sales |
Gross
|
Net |
|
12 |
29/03/2007 |
194101 |
56285 |
46608 |
|
12 |
29/03/2006 |
174380 |
51821 |
39557 |
|
12 |
29/03/2005 |
166540 |
48335 |
33770 |
BALANCE SHEET
Source: Financial Estimates on 29/03/2006
Currency: Iranian Rials
Note: Figures in 000,000
|
NEW WORTH |
104600 |
|
Trade Creditor |
39000 |
|
Total Liabilities |
91700 |
|
|
|
|
Trade Debtors |
56000 |
|
Total Assets |
179300 |
Payments
Subject's payments reported to be: NO COMPLAINTS
interview
& reporter comments
Name/Title: Ms. Kimia Rashad (Secretary)
In the interview conducted with Ms. Kimia Rashad (Secretary), She declined bank account numbers citing the grounds of Company
confidentiality.
Conclusion
Local Reputation: The company being investigated is considered by local reporters to be a
Normal Trade Risk.
General Conclusion:
Local informants consider granting of credit to be a fair trade risk.
Owner/Shareholders Comments:
Some of owners involved in the running of
the business
Age of Business: Old
Business
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)